Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + zolpidem-Eisai Inc.-insomnia
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The designation placebo + zolpidem-Eisai Inc.-insomnia refers to the control interventions used in clinical trials sponsored by Eisai Inc., specifically in the evaluation of the abuse potential of the dual orexin receptor antagonist lemborexant (NCT03158025). This group includes a placebo as a negative control and zolpidem as a positive control. Zolpidem is a non-benzodiazepine hypnotic of the imidazopyridine class that acts as a positive allosteric modulator of the GABA-A receptor, with high affinity for the alpha-1 subunit. It is widely approved for the short-term treatment of insomnia characterized by difficulties with sleep initiation. In the context of the Eisai study, zolpidem was administered at a supratherapeutic dose (30 mg) to healthy recreational sedative users to provide a benchmark for comparing the sedative and reinforcing effects of investigational compounds.
- Other names
- placebozolpidemzolpidem tartrate
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on placebo + zolpidem-Eisai Inc.-insomnia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + zolpidem-Eisai Inc.-insomnia.